296 related articles for article (PubMed ID: 32639068)
41. Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.
Dmello C; Zhao J; Chen L; Gould A; Castro B; Arrieta VA; Zhang DY; Kim KS; Kanojia D; Zhang P; Miska J; Yeeravalli R; Habashy K; Saganty R; Kang SJ; Fares J; Liu C; Dunn G; Bartom E; Schipma MJ; Hsu PD; Alghamri MS; Lesniak MS; Heimberger AB; Rabadan R; Lee-Chang C; Sonabend AM
Nat Commun; 2023 Mar; 14(1):1566. PubMed ID: 36949040
[TBL] [Abstract][Full Text] [Related]
42. Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
Shida Y; Nakazawa T; Matsuda R; Morimoto T; Nishimura F; Nakamura M; Maeoka R; Yamada S; Nakagawa I; Park YS; Yasukawa M; Tojo T; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576141
[TBL] [Abstract][Full Text] [Related]
43. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma.
Goswami S; Walle T; Cornish AE; Basu S; Anandhan S; Fernandez I; Vence L; Blando J; Zhao H; Yadav SS; Ott M; Kong LY; Heimberger AB; de Groot J; Sepesi B; Overman M; Kopetz S; Allison JP; Pe'er D; Sharma P
Nat Med; 2020 Jan; 26(1):39-46. PubMed ID: 31873309
[TBL] [Abstract][Full Text] [Related]
44. Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes.
Alcantara Llaguno SR; Wang Z; Sun D; Chen J; Xu J; Kim E; Hatanpaa KJ; Raisanen JM; Burns DK; Johnson JE; Parada LF
Cancer Cell; 2015 Oct; 28(4):429-440. PubMed ID: 26461091
[TBL] [Abstract][Full Text] [Related]
45. Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells.
Mukherjee S; Fried A; Hussaini R; White R; Baidoo J; Yalamanchi S; Banerjee P
J Exp Clin Cancer Res; 2018 Jul; 37(1):168. PubMed ID: 30041669
[TBL] [Abstract][Full Text] [Related]
46. Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma.
Chen Z; Soni N; Pinero G; Giotti B; Eddins DJ; Lindblad KE; Ross JL; Puigdelloses Vallcorba M; Joshi T; Angione A; Thomason W; Keane A; Tsankova NM; Gutmann DH; Lira SA; Lujambio A; Ghosn EEB; Tsankov AM; Hambardzumyan D
Nat Commun; 2023 Apr; 14(1):1839. PubMed ID: 37012245
[TBL] [Abstract][Full Text] [Related]
47. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.
Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC
PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882
[TBL] [Abstract][Full Text] [Related]
49. Immunotherapy for glioblastoma: the promise of combination strategies.
Bausart M; Préat V; Malfanti A
J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
[TBL] [Abstract][Full Text] [Related]
50. Molecular Mechanisms of Drug Resistance in Glioblastoma.
Dymova MA; Kuligina EV; Richter VA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
[TBL] [Abstract][Full Text] [Related]
51. Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.
Long S; Li M; Liu J; Yang Y; Li G
Aging (Albany NY); 2020 Apr; 12(8):7112-7128. PubMed ID: 32310827
[TBL] [Abstract][Full Text] [Related]
52. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
[TBL] [Abstract][Full Text] [Related]
53. The immune landscape of high-grade brain tumor after treatment with immune checkpoint blockade.
Park JH; Kang I; Lee HK
Front Immunol; 2022; 13():1044544. PubMed ID: 36591276
[TBL] [Abstract][Full Text] [Related]
54. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
55. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
Sinnadurai M; McDonald KL
J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
[TBL] [Abstract][Full Text] [Related]
56. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
57. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment.
Li TF; Li K; Wang C; Liu X; Wen Y; Xu YH; Zhang Q; Zhao QY; Shao M; Li YZ; Han M; Komatsu N; Zhao L; Chen X
J Control Release; 2017 Dec; 268():128-146. PubMed ID: 29051064
[TBL] [Abstract][Full Text] [Related]
58. Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism.
Lee CAA; Banerjee P; Wilson BJ; Wu S; Guo Q; Berg G; Karpova S; Mishra A; Lian JW; Tran J; Emmerich M; Murphy GF; Frank MH; Frank NY
J Biol Chem; 2020 May; 295(22):7774-7788. PubMed ID: 32317280
[TBL] [Abstract][Full Text] [Related]
59. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
60. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
